Lipopolysaccharide from E. coli 0111:B4

(No reviews yet) Write a Review
SKU:
445-9028
Size:
0.5 mg/ml x 5 ml
Shipping:
Gel Packs
Storage:
-20 C
Select Currency //321.00

 Select your currency from the header

Description

Lipopolysaccharide from E. coli 0111:B4 - Cat Number: 9028 From Chondrex.

Research Field: Arthritis, Bacterial Research

Clonality: N/A

Cross-Reactivity:

Host Origin: N/A

Applications: N/A

Isotype: N/A

Detection Range: N/A

Sample Type: N/A

Concentration: 0.5 mg/ml

Immunogen:

DESCRIPTION: Lipopolysaccharide (LPS) from E. Coli O111:B4 in 0.05M phosphate buffered saline, pH 7.4
APPLICATION: LPS has two independent unique activities: one is triggering inflammatory reactions and the
other is stimulating B-cells to produce antibodies. Use these unique properties of LPS to trigger,
synchronize, or enhance the development of arthritis in both collagen-induced arthritis (CIA)
and collagen antibody-induced arthritis (CAIA) models.
A. CAIA model: Use LPS to trigger arthritis in mice in the presence of sub-arthritogenic levels
of autoantibodies to type II collagen.
1. Inject a sub-arthritogenic dose of polyclonal antibodies or a cocktail of monoclonal
antibodies into mice on day 0 and then inject 25-50 µg of LPS by IP injection to trigger
the development of arthritis.
2. An additional IP injection of LPS on day 7-14 re-activates arthritis.
B. CIA model: Use LPS to stimulate autoantibody production and development of arthritis in
mice immunized with type II collagen.
1. To synchronize arthritis development: immunize mice with type II collagen/CFA on
day 0 and then inject 25-50 µg of LPS by IP injection on day 25-28, just before the
expected onset of arthritis.
2. To stimulate antibody production and development of arthritis: immunize mice with
type II collagen/CFA on day 0 and then inject 20-50 µg of LPS by IP injection on day
21 or 28 to increase antibody production and the following development of arthritis.
3. To reactivate arthritis: Inject 25-50 µg of LPS by IP injection in mice on day 50-80,
the late stage of CIA.
C. LPS is also used at low levels (0.01-1 µg/ml) as a positive control in vitro for stimulating
the production and release of cytokines and chemokines.
QUANTITY: 5 ml
FORM: 0.5 mg/ml solution
SOURCE: E. Coli O111:B4
STORAGE: -20°C
STABILITY: 1 year
NOTES: N/A
REFERENCES: N/A

View AllClose

0 Reviews

View AllClose